|

PD-1 blocking antibody Clinical Trials

2 actively recruiting trials

Also known as: Camrelizumab, JS001

Pipeline

Phase 3: 2

Top Sponsors

  • Sun Yat-sen University2

Indications

  • Cancer2
  • Recurrent Nasopharyngeal Carcinoma1
  • Nasopharyngeal Carcinoma1

Other2 trials

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
Phase 3
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.